Clinical trial

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

NCT00212290

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-11-01

PhasePHASE4

Study timeline

Study start (unknown)2002-11-01Date precision: month

Registry last updated2010-02-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Insulin Resistanceunresolved

Type 2 Diabetes Mellitusunresolved

Interventions

pioglitazoneDRUG · verified · RxNorm: pioglitazone

nateglinideDRUG · verified · RxNorm: nateglinide

placeboDRUG

Sponsors & collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)lead sponsor

Mapped research locations

SeattleWashington, United States1 TacomaWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00212290 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.